HemCon Medical Technologies, a developer, manufacturer and marketer of technologies to control bleeding and infection resulting from trauma or surgery, has appointed Nick Hart as president, effective 24 January 2011.
Hart has served as the company’s chief financial officer, following HemCon’s acquisition of Alltracel Pharmaceuticals in 2008, and has over 20 years of financial experience in the life sciences sector.
Chairman of the Board William Wiesmann said Nick is not only a skilled chief financial officer, but has the leadership and strategic vision required to move into the role of president to lead HemCon as it prepares to introduce new products in the US and internationally over the next twelve months.
"We are pleased to announce his appointment. Nick has the full confidence of the Board and signifies a new era of management. Nick’s international experience and business skills will be increasingly important as HemCon enters into these new markets and product launches," Wiesmann said.
Hart said he was honored to lead the HemCon team and welcomes the opportunity to look forward in growing the company.